The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii

Joly-Guillou, 2005, Clinical impact and pathogenicity of Acinetobacter, Clin Microbiol Infect, 11, 868, 10.1111/j.1469-0691.2005.01227.x Cisneros, 2002, Nosocomial bacteriemia due to Acinetobacter baumannii: epidemiology, clinical features and treatment, Clin Microbiol Infect, 8, 687, 10.1046/j.1469-0691.2002.00487.x Jamulitrat, 2009, Attributable mortality of imipenem-resistant nosocomial Acinetobacter baumannii bloodstream infection, J Med Assoc Thailand, 92, 413 Garnacho-Montero, 2015, Task force on management and prevention of Acinetobacter baumannii infections in the ICU, Intensive Care Med, 41, 2057, 10.1007/s00134-015-4079-4 Maragakis, 2008, Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options, Clin Infect Dis, 46, 1254, 10.1086/529198 Kuo, 2007, Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome, Clin Microbiol Infect, 13, 196, 10.1111/j.1469-0691.2006.01601.x Durante-Mangoni, 2013, Colistin and Rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial, Clin Infect Dis, 57, 349, 10.1093/cid/cit253 Clinical and Laboratory Standard Institute, 2012 Knaus, 1985, APACHE II: a severity of disease classification system, Crit Care Med, 13, 818, 10.1097/00003246-198510000-00009 Charlson, 1987, A new method of classifying prognostic co-morbidity in longitudinal studies: development and validation, J Chron Dis, 40, 373, 10.1016/0021-9681(87)90171-8 Mehta, 2007, Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury, Crit Care, 11, R31, 10.1186/cc5713 Oliveira, 2008, Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp, J Antimicrob Chemoth, 61, 1369, 10.1093/jac/dkn128 Routsi, 2010, Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes, Infection, 38, 173, 10.1007/s15010-010-0008-1 Molina, 2009, Aminoglucósidos y polimixinas, Enferm Infec Micr Cl, 27, 178, 10.1016/j.eimc.2009.02.001 Paul, 2010, Effectiveness and safety of colistin: prospective comparative cohort study, J Antimicrob Chemother, 65, 1019, 10.1093/jac/dkq069 Giamarellou, 2011, Pharmacokinetic and pharmacodynamic evaluation of tigecycline, Expert Opin Drug Met, 7, 1459, 10.1517/17425255.2011.623126 Zusman, 2017, Polymixin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis, J Antimicrob Chemoth, 72, 29, 10.1093/jac/dkw377 Bae, 2016, In vitro synergistic activity of antimicrobial agents in combination against clinical isolates of colistin-resistant Acinetobacter baumannii, Antimicrob Agents Chemother, 60, 6774, 10.1128/AAC.00839-16 Pankey, 2005, Tigecycline, J Antimicrob Chemother, 56, 470, 10.1093/jac/dki248 Kasbekar, 2006, Tigecycline: a new glycylcycline antimicrobial agent, Am J Health-Syst Pharm, 63, 1235, 10.2146/ajhp050487 Dafopoulou, 2015, Comparative evaluation of colistin susceptibility testing methods among carbapenem-nonsusceptible Klebsiella pneumoniae and Acinetobacter baumannii clinical isolates, Antimicrob Agents Chemother, 59, 4625, 10.1128/AAC.00868-15 Meagher, 2007, Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections, Antimicrob Agents Chemother, 51, 1939, 10.1128/AAC.01084-06 Poulakou, 2009, Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens, J Infect, 58, 273 Rodvold, 2006, Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose, J Antimicrob Chemother, 58, 1221, 10.1093/jac/dkl403 Principe, 2009, In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii, Ann Clin Microbiol Antimicrob, 8, 18, 10.1186/1476-0711-8-18 Teng, 2015, Comparison of pneumonia and non-pneumonia-related Acinetobacter baumannii bacteremia: impact on empiric therapy and antibiotic resistance, J Microbiol Immunol Infect, 48, 525, 10.1016/j.jmii.2014.06.011